DEVELOPMENT AND EVALUATION OF DOLUTEGRAVIR BASED LIQUISOLID COMPACTS AND FAST-DISINTEGRATING TABLETS FOR ENHANCED DISSOLUTION

Authors

  • Ms.Krupaben Pravinbhai Patel Author
  • Dr.Sunil Thakral Author

DOI:

https://doi.org/10.4238/11ezvz22

Keywords:

Dolutegravir; liquisolid compacts; fast-disintegrating tablets; propylene glycol; factorial design; FTIR; dissolution enhancement.

Abstract

Background: Dolutegravir, an HIV-1 integrase strand-transfer inhibitor, is reported in the supplied study to have limited aqueous solubility. Liquisolid technology converts a drug-containing non-volatile liquid medication into a dry, compressible powder using carrier and coating materials. Objective: To develop and optimize Dolutegravir liquisolid compacts using a 3² factorial design and evaluate their conversion into fast-disintegrating tablets. Methods: Dolutegravir (5 mg) was incorporated into propylene glycol (PG), with Avicel PH 102 and Aerosil used as carrier and coating materials, respectively. The effects of carrier-to-coating ratio (10:1, 15:1 and 20:1) and PG volume (0.02, 0.04 and 0.06 mL) were studied for wetting time, disintegration time and 30-min cumulative drug release. Two checkpoint formulations were compared with model-predicted responses. The selected liquisolid formulation was compressed into fast-disintegrating tablets using Kyron T-314 and aspartame. Preformulation included UV spectrophotometry and FTIR analysis. Results: DLSCT10 (15:1; 0.06 mL PG) was selected as the optimized checkpoint formulation and showed wetting time of 73.14 s, disintegration time of 22.50 s and 93.05% drug release at 30 min, compared with predicted values of 71.96 s, 21.55 s and 92.76%. Fast-disintegrating tablet Batch 1 showed drug content of 96.37 ± 0.16% and 94.03 ± 1.18% release at 10 min, versus 32.65 ± 1.97% for the marketed tablet. FTIR bands were reported at 3167, 1648, 1321, 1272, 1083 and 765 cm⁻¹. Conclusion: The reported in-vitro findings support further development of Dolutegravir liquisolid compacts and fast disintegrating tablets. Several source-data inconsistencies, including the pure-drug solubility, calibration and formulation mass balance, require verification before submission.

Downloads

Published

2026-11-04

Issue

Section

Articles